- FDA approves Nuvalent's cancer drug, a week after GSK closed $10.6B buyoutGSK's $10.6 billion acquisition of Nuvalent is delivering surprisingly early results. The FDA on Wednesday approved one of Nuvalent's lung cancer medicines two months earlier than projected, and…Endpoints · 1d ago↗ source
- Arrowhead’s gene silencer competitive with Ionis’ in triglyceride diseaseArrowhead Pharmaceuticals’ lipid-lowering drug has hit in two late-stage trials that could expand its use into a much wider population. Data shared Wednesday showed that Arrowhead’s gene silencer…Endpoints · 2d ago↗ source
- Mentari adds $200M to migraine mission; Royalty's latest ATTR-CM dealAnother $200M for Mentari: Migraine drug developer Mentari Therapeutics has lined up a second private placement as it works to close its reverse merger with InMed Pharmaceuticals. The Paragon Thera…